Swiss National Bank’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Swiss National Bank’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-98,200	Closed	-$254K	–	2621
2023 Q2	$254K	Buy	98,200 +36,500	+59%	+$130K	﹤0.01%	2598
2023 Q1	$252K	Sell	61,700 -4,100	-6%	-$18.9K	﹤0.01%	2625
2022 Q4	$330K	Hold	65,800	–	–	﹤0.01%	2641
2022 Q3	$861K	Buy	65,800 +1,800	+3%	+$27.3K	﹤0.01%	2409
2022 Q2	$820K	Sell	64,000 -9,500	-13%	-$132K	﹤0.01%	2467
2022 Q1	$1.12M	Buy	73,500 +5,900	+9%	+$92K	﹤0.01%	2356
2021 Q4	$1.2M	Hold	67,600	–	–	﹤0.01%	2372
2021 Q3	$1.42M	Hold	67,600	–	–	﹤0.01%	2250
2021 Q2	$1.33M	Buy	+67,600	New	+$1.58M	﹤0.01%	2339

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swiss National Bank's NGM Position: Q3 2023 in Review

Swiss National Bank sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 98,200 shares — an estimated $254K sold.

Swiss National Bank first reported a position in NGM in Q2 2021 and held it in 9 quarters. The position peaked at $1.42M in Q3 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

Swiss National Bank reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Swiss National Bank sold 98,200 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $254K.
Swiss National Bank first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Swiss National Bank's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.42M in Q3 2021.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Swiss National Bank's 13F filing for Q3 2023, filed 8 Nov 2023.